The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Venetoclax monotherapy in MCL: longer-term results
Matthew Davids, MD, MSc, of Dana-Farber Cancer Institute, Boston, MA, discusses the results from the longer-term follow-up of mantle cell lymphoma (MCL) patients treated with venetoclax monotherapy (NCT01328626), now with a median of 27 months, which he presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA. Dr Davids then gives his insight into the future directions for the use of venetoclax in MCL.
